C3a antibody | 048-18.6.3.X (10-21)
C3a mediates local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. C3a is expressed at significantly higher levels in colorectal cancer.
Mouse anti Human C3a antibody, clone 10-21 shows minimal reactivity with other complement proteins in radioimmunoassays and haemagglutination.
Mouse anti Human C3a antibody, clone 10-21 has been reported to work in western blotting applications.
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Borate buffered saline
- Preservative Stabilisers
- 0.1% Sodium Azide (NaN3)
- Native purified human C3a.
- Approx. Protein Concentrations
- Please see label for concentration
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- Guaranteed until date of expiry. Please see product label.
- Entrez Gene
- GO Terms
- GO:0005102 receptor binding
- GO:0004866 endopeptidase inhibitor activity
- GO:0005615 extracellular space
- GO:0006954 inflammatory response
- GO:0006957 complement activation, alternative pathway
- GO:0006958 complement activation, classical pathway
- GO:0007186 G-protein coupled receptor protein signaling pathway
- GO:0010575 positive regulation vascular endothelial growth factor production
- For research purposes only
Applications of C3a antibody
|Application Name||Verified||Min Dilution||Max Dilution|
Secondary Antibodies Available
Product Specific References
Hugli, T.E. (1975) Human anaphylatoxin (C3a) from the third component of complement. Primary structure.
J Biol Chem. 250 (21): 8293-301.
Habermann, J.K. et al. (2006) Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors.
Gastroenterology. 131 (4): 1020-9; quiz 1284.